{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:32:35Z","timestamp":1791898355492,"version":"4.3.4"},"reference-count":140,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"1","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precis Oncol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>High levels of DNA replication stress and defects in the DNA damage response (DDR) pathways are vulnerabilities of many poor prognosis childhood malignancies. Ataxia telangiectasia and Rad3-related protein (ATR) is a key regulator of these pathways and constitutes an attractive target, especially in combination. However, the malignancies where ATR inhibitors have maximum benefit and synergistic combinations differ between adults and children.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DESIGN<\/jats:title>\n                    <jats:p>ACCELERATE convened a multistakeholder meeting and conducted review and analysis to propose the optimal pathway for the development of ATR inhibitors in pediatric malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Considering the lack of identified biomarkers, the initial evaluation of ATR inhibitors should focus on Ewing sarcoma, rhabdomyosarcoma, and neuroblastoma in view of their high levels of DNA replication stress and defects in DDR pathways. Early phase trials of ATR inhibitors should be iterative, based on a clear hypothesis with responders and nonresponders undergoing detailed molecular analysis and a revised new hypothesis generated. Trial designs should restrict monotherapy evaluation to a brief exposure in a small number of patients and progress rapidly to combinations. Highlighted combination partners are poly(ADP-ribose) polymerase inhibitors and antibody drug conjugates with topoisomerase I inhibitor payloads. Combinations with ALK inhibitors (in\n                      <jats:italic toggle=\"yes\">ALK<\/jats:italic>\n                      \/\n                      <jats:italic toggle=\"yes\">MYCN<\/jats:italic>\n                      -aberrant neuroblastoma) and aurora A kinase (in\n                      <jats:italic toggle=\"yes\">MYCN<\/jats:italic>\n                      -amplified) are supported by robust mechanisms of action and preclinical data. Early interactions with regulators are crucial, and early phase clinical trials should be conducted in regulatory-approved, academic-sponsored, industry-supported, platform trials.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>ATR inhibitors are a prototype for the development of medicinal products in a limited pediatric population. For the substantial potential of ATR inhibitors in children with malignancy to be realized, strategic planning between academia, industry, regulators, and patient advocates is vital.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/po-25-00642","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:59:11Z","timestamp":1768510751000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":2,"title":["Pathway for the Development of ATR Inhibitors in Pediatric Malignancies: An ACCELERATE Multistakeholder Analysis"],"prefix":"10.1200","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6438-9778","authenticated-orcid":true,"given":"Susanne A.","family":"Gatz","sequence":"first","affiliation":[{"name":"Department of Cancer and Genomic Sciences, School of Medical Sciences, College of Medicine and Health, University of Birmingham, Birmingham, United Kingdom"},{"name":"Department of Paediatric Oncology, Women's and Children's NHS Foundation Trust, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5316-6440","authenticated-orcid":true,"given":"Julia","family":"Glade-Bender","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Centre, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8738-5913","authenticated-orcid":true,"given":"Andrew D.J.","family":"Pearson","sequence":"additional","affiliation":[{"name":"ACCELERATE, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9379-314X","authenticated-orcid":true,"given":"Michael V.","family":"Ortiz","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Centre, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Bernardi","sequence":"additional","affiliation":[{"name":"Genentech, A Member of the Roche Group, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7842-2068","authenticated-orcid":true,"given":"Lou","family":"Chesler","sequence":"additional","affiliation":[{"name":"Institute of Cancer Research, Sutton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8573-8009","authenticated-orcid":true,"given":"Steve","family":"Clifford","sequence":"additional","affiliation":[{"name":"Newcastle University Centre for Cancer, Newcastle-upon-Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8852-1104","authenticated-orcid":true,"given":"Sarah","family":"Cohen-Gogo","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7072-1493","authenticated-orcid":true,"given":"Esther","family":"De La Cuesta","sequence":"additional","affiliation":[{"name":"Bayer HealthCare Pharmaceuticals, Inc, Whippany, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7749-8423","authenticated-orcid":true,"given":"Teresa","family":"de Rojas","sequence":"additional","affiliation":[{"name":"ACCELERATE, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1762-5739","authenticated-orcid":true,"given":"Kaat","family":"Durinck","sequence":"additional","affiliation":[{"name":"Department of Biomolecular Medicine, Ghent University, Ghent, Belgium"},{"name":"Cancer Research Institute Ghent (CRIG), Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5807-4876","authenticated-orcid":true,"given":"Sara","family":"Federico","sequence":"additional","affiliation":[{"name":"Department of Oncology, St Jude Children's Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9998-5326","authenticated-orcid":true,"given":"Elizabeth","family":"Fox","sequence":"additional","affiliation":[{"name":"Department of Oncology, St Jude Children's Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2777-4922","authenticated-orcid":true,"given":"Sally","family":"George","sequence":"additional","affiliation":[{"name":"Institute of Cancer Research, Sutton, United Kingdom"},{"name":"The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2755-6597","authenticated-orcid":true,"given":"Ioannis","family":"Gounaris","sequence":"additional","affiliation":[{"name":"Merck Serono Ltd, Feltham, United Kingdom, an affiliate of Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1534-778X","authenticated-orcid":true,"given":"Anton George","family":"Henssen","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2452-5181","authenticated-orcid":true,"given":"Meredith","family":"Irwin","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Kool","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric oncology, Utrecht, the Netherlands"},{"name":"University Medical Center Utrecht (UMCU), Utrecht, the Netherlands"},{"name":"Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany"},{"name":"German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1055-9812","authenticated-orcid":true,"given":"Alan","family":"Lau","sequence":"additional","affiliation":[{"name":"AstraZeneca, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2935-0058","authenticated-orcid":true,"given":"Karsten","family":"Nysom","sequence":"additional","affiliation":[{"name":"Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5338-3979","authenticated-orcid":true,"given":"Alberto","family":"Pappo","sequence":"additional","affiliation":[{"name":"Department of Oncology, St Jude Children's Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory K.","family":"Pennock","sequence":"additional","affiliation":[{"name":"EMD Serono, Billerica, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan M.","family":"Pfister","sequence":"additional","affiliation":[{"name":"Hopp Children's Cancer Center Heidelberg (KiTZ)\/Division of Pediatric Neurooncology, DKFZ\/KiTZ, Clinical Trial Unit and Childhood Brain Tumors, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6539-2741","authenticated-orcid":true,"given":"Nicole","family":"Scobie","sequence":"additional","affiliation":[{"name":"ACCELERATE, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4463-5759","authenticated-orcid":true,"given":"Emily K.","family":"Slotkin","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Centre, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9880-9876","authenticated-orcid":true,"given":"Malcolm","family":"Smith","sequence":"additional","affiliation":[{"name":"National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Speleman","sequence":"additional","affiliation":[{"name":"Department of Biomolecular Medicine, Ghent University, Ghent, Belgium"},{"name":"Cancer Research Institute Ghent (CRIG), Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Stewart","sequence":"additional","affiliation":[{"name":"Department of Oncology, St Jude Children's Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1080-1402","authenticated-orcid":true,"given":"Brenda J.","family":"Weigel","sequence":"additional","affiliation":[{"name":"Department of Oncology, St Jude Children's Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1780-8869","authenticated-orcid":true,"given":"Gilles","family":"Vassal","sequence":"additional","affiliation":[{"name":"ACCELERATE, Brussels, Belgium"},{"name":"Gustave Roussy Cancer Centre, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00863-5"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.107450"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2014.09.028"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature25748"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xgen.2023.100402"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115537"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32023-7"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920956900"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-016-0389-6"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.10.029"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.01.033"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.112950"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2015.10.040"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2017.05.015"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01388"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncb2897"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1461"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrm.2017.67"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncb3415"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncb3422"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2015.07.029"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0479"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2016.12.007"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-012414-040424"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abn1382"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature03445"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz192"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0114-z"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.420"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4245-13.2014"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00418-017-1591-3"},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.243"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1867"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","unstructured":"Konstantinopoulos PA Cheng SC Lee EK et al: Randomized phase II study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: Final overall survival and biomarker analyses. JCO Precis Oncol 10.1200\/PO.23.00635","DOI":"10.1200\/PO.23.00635"},{"key":"e_1_3_6_36_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-2997"},{"key":"e_1_3_6_37_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1032"},{"key":"e_1_3_6_38_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0868"},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-024-04745-6"},{"key":"e_1_3_6_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djae098"},{"key":"e_1_3_6_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02399-0"},{"key":"e_1_3_6_42_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-2409"},{"key":"e_1_3_6_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.1866"},{"key":"e_1_3_6_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02404"},{"key":"e_1_3_6_45_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI175369"},{"key":"e_1_3_6_46_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-1500"},{"key":"e_1_3_6_47_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-3126"},{"key":"e_1_3_6_48_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-022-00558-5"},{"key":"e_1_3_6_49_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12266"},{"key":"e_1_3_6_50_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005041"},{"key":"e_1_3_6_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.10.009"},{"key":"e_1_3_6_52_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature25480"},{"key":"e_1_3_6_53_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1072-4"},{"key":"e_1_3_6_54_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1631"},{"key":"e_1_3_6_55_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-1136"},{"key":"e_1_3_6_56_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02838"},{"key":"e_1_3_6_57_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1503"},{"key":"e_1_3_6_58_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy028"},{"key":"e_1_3_6_59_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0593"},{"key":"e_1_3_6_60_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27329"},{"key":"e_1_3_6_61_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI58928"},{"key":"e_1_3_6_62_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-1707"},{"key":"e_1_3_6_63_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-23-0094"},{"key":"e_1_3_6_64_2","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-19-0585"},{"key":"e_1_3_6_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tig.2017.09.003"},{"key":"e_1_3_6_66_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1257216"},{"key":"e_1_3_6_67_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2016.00186"},{"key":"e_1_3_6_68_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-021-00363-6"},{"key":"e_1_3_6_69_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd5750"},{"key":"e_1_3_6_70_2","volume-title":"European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (ESMART)","unstructured":"European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (ESMART). clinicaltrials.gov\/study\/NCT02813135"},{"key":"e_1_3_6_71_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02580-5"},{"key":"e_1_3_6_72_2","article-title":"Phase I\/II study of the PARP inhibitor olaparib and ATR inhibitor ceralasertib in children with advanced malignancies: Arm N of the AcS\u00e9-ESMART trial","volume":"83","author":"Gatz SA","year":"2023","unstructured":"Gatz SA, San Sim\u00f3n AR, Archambaud B, et al: Phase I\/II study of the PARP inhibitor olaparib and ATR inhibitor ceralasertib in children with advanced malignancies: Arm N of the AcS\u00e9-ESMART trial. Cancer Res 83, 2023 (suppl 8; abstr CT019)","journal-title":"Cancer Res"},{"key":"e_1_3_6_73_2","volume-title":"Olaparib With Ceralasertib in Recurrent Osteosarcoma","unstructured":"Olaparib With Ceralasertib in Recurrent Osteosarcoma. https:\/\/clinicaltrials.gov\/study\/NCT04417062"},{"key":"e_1_3_6_74_2","article-title":"Phase II trial of olaparib in combination with ceralasertib in patients with recurrent osteosarcoma","volume":"39","author":"Forrest SJ","year":"2023","unstructured":"Forrest SJ, Kinnaman MD, Livingston JA, et al: Phase II trial of olaparib in combination with ceralasertib in patients with recurrent osteosarcoma. J Clin Oncol 39, 2023 (suppl 15; abstr TPS11575)","journal-title":"J Clin Oncol"},{"key":"e_1_3_6_75_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.10005"},{"key":"e_1_3_6_76_2","volume-title":"Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors","unstructured":"Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors. https:\/\/clinicaltrials.gov\/study\/NCT05071209"},{"key":"e_1_3_6_77_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e15131"},{"key":"e_1_3_6_78_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0916"},{"key":"e_1_3_6_79_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13184601"},{"key":"e_1_3_6_80_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00445-1"},{"key":"e_1_3_6_81_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00474-y"},{"key":"e_1_3_6_82_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.5689"},{"key":"e_1_3_6_83_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03044-0"},{"key":"e_1_3_6_84_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30233-7"},{"key":"e_1_3_6_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.09.001"},{"key":"e_1_3_6_86_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03056-w"},{"key":"e_1_3_6_87_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28031143"},{"key":"e_1_3_6_88_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-022-00896-2"},{"key":"e_1_3_6_89_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1399442"},{"key":"e_1_3_6_90_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gks781"},{"key":"e_1_3_6_91_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1587"},{"key":"e_1_3_6_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2021.100569"},{"key":"e_1_3_6_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymeth.2016.08.016"},{"key":"e_1_3_6_94_2","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-24-0338"},{"key":"e_1_3_6_95_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.09.042"},{"key":"e_1_3_6_96_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38195-0"},{"key":"e_1_3_6_97_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-0753"},{"key":"e_1_3_6_98_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00660-y"},{"key":"e_1_3_6_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.05.520"},{"key":"e_1_3_6_100_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00509-4"},{"key":"e_1_3_6_101_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.09.043"},{"key":"e_1_3_6_102_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-02162-0"},{"key":"e_1_3_6_103_2","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-22-0168"},{"key":"e_1_3_6_104_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-024-01413-5"},{"key":"e_1_3_6_105_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111081"},{"key":"e_1_3_6_106_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0606-4"},{"key":"e_1_3_6_107_2","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.190156"},{"key":"e_1_3_6_108_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00518-6"},{"key":"e_1_3_6_109_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01548-8"},{"key":"e_1_3_6_110_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2315242121"},{"key":"e_1_3_6_111_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2008.12.005"},{"key":"e_1_3_6_112_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-00171-8"},{"key":"e_1_3_6_113_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-2753"},{"key":"e_1_3_6_114_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-4340"},{"key":"e_1_3_6_115_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2273"},{"key":"e_1_3_6_116_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-1328-y"},{"key":"e_1_3_6_117_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15981"},{"key":"e_1_3_6_118_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.290957.116"},{"key":"e_1_3_6_119_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0615"},{"key":"e_1_3_6_120_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c01012"},{"key":"e_1_3_6_121_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-CT007"},{"key":"e_1_3_6_122_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27057-2"},{"key":"e_1_3_6_123_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1047"},{"key":"e_1_3_6_124_2","doi-asserted-by":"publisher","DOI":"10.1038\/s44320-025-00085-6"},{"key":"e_1_3_6_125_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0536"},{"key":"e_1_3_6_126_2","first-page":"161","article-title":"Combined inhibition of PARP and ATR synergistically potentiates the antitumor activity of HER2-targeting antibody-drug conjugate in HER2-positive cancers","volume":"13","author":"Li Y","year":"2023","unstructured":"Li Y, Li L, Fu H, et al: Combined inhibition of PARP and ATR synergistically potentiates the antitumor activity of HER2-targeting antibody-drug conjugate in HER2-positive cancers. Am J Cancer Res 13:161-175, 2023","journal-title":"Am J Cancer Res"},{"key":"e_1_3_6_127_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.165615"},{"key":"e_1_3_6_128_2","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ado4618"},{"key":"e_1_3_6_129_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02430"},{"key":"e_1_3_6_130_2","first-page":"758759","article-title":"Efficacy of ATR inhibitors as single agents in Ewing sarcoma","author":"Nieto-Soler M","year":"2016","unstructured":"Nieto-Soler M, Morgado-Palacin I, Lafarga V, et al: Efficacy of ATR inhibitors as single agents in Ewing sarcoma. Oncotarget:758759-758767, 2016","journal-title":"Oncotarget"},{"key":"e_1_3_6_131_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114201"},{"key":"e_1_3_6_132_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.49239"},{"key":"e_1_3_6_133_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12609-019-00334-2"},{"key":"e_1_3_6_134_2","volume-title":"Childhood Cancer Academic-Industry Collaborative: Platform Trials","unstructured":"Childhood Cancer Academic-Industry Collaborative: Platform Trials. https:\/\/mrctcenter.org\/platform-oncology"},{"key":"e_1_3_6_135_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.04.038"},{"key":"e_1_3_6_136_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114145"},{"key":"e_1_3_6_137_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.01.018"},{"key":"e_1_3_6_138_2","volume-title":"Targeted Therapy Directed by Genetic Testing in Treating Patients with Locally Advanced or Advanced Solid Tumors, the ComboMATCH Screening Trial","unstructured":"Targeted Therapy Directed by Genetic Testing in Treating Patients with Locally Advanced or Advanced Solid Tumors, the ComboMATCH Screening Trial. https:\/\/clinicaltrials.gov\/study\/NCT05564377"},{"key":"e_1_3_6_139_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0917"},{"key":"e_1_3_6_140_2","volume-title":"A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (Glo-BNHL)","unstructured":"A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (Glo-BNHL). https:\/\/clinicaltrials.gov\/study\/NCT05991388"},{"key":"e_1_3_6_141_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.09.025"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO-25-00642","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T15:47:46Z","timestamp":1772812066000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO-25-00642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":140,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1200\/PO-25-00642"],"URL":"https:\/\/doi.org\/10.1200\/po-25-00642","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-07-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2500642"}}